Advanced Biomed Inc. (NASDAQ:ADVB) Short Interest Up 441.2% in July

Advanced Biomed Inc. (NASDAQ:ADVB) was the target of a large increase in short interest in July. As of July 31st, there was short interest totaling 57,213 shares, an increase of 441.2% from the July 15th total of 10,571 shares. Based on an average trading volume of 8,635,838 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.7% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Advanced Biomed has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Advanced Biomed stock. BlackRock Inc. bought a new position in shares of Advanced Biomed Inc. (NASDAQ:ADVB) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 59,944 shares of the company’s stock, valued at approximately $186,000. BlackRock Inc. owned about 3.63% of Advanced Biomed as of its most recent SEC filing.

Advanced Biomed Trading Down 1.8%

ADVB stock opened at $7.77 on Wednesday. Advanced Biomed has a 12-month low of $3.61 and a 12-month high of $24.23. The business has a 50-day moving average price of $6.57. The firm has a market cap of $12.84 million, a PE ratio of 1.61 and a beta of -0.41.

Advanced Biomed (NASDAQ:ADVB) last announced its earnings results on Saturday, May 16th. The company reported ($0.38) EPS for the quarter.

Advanced Biomed Company Profile

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.